Skip to main content
Results: 3 to 4 Weeks Sample: Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA Card

Test Price

2,800 AED

โœ… Home Collection Available

๐Ÿ“‹ Results in 3 to 4 Weeks

COL5A1 Gene Ehlers-Danlos Syndrome Type 1/2 Genetic Test in UAE โ€“ 2,800 AED

DHA Licensed Facility: 1143 ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) NGS Technology

2,800 AED

TAT: 3 to 4 Weeks

Executive Summary & Core Metrics

This advanced genetic analysis using Next-Generation Sequencing (NGS) technology provides a definitive molecular diagnosis for Classical Ehlers-Danlos Syndrome associated with the COL5A1 gene, delivering 99.9% diagnostic sensitivity through ISO-accredited processing within the UAE. This test empowers clinicians with precise genomic data to confirm cEDS Type 1/2 and guide multidisciplinary management strategies.

  • โœ“ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
  • โœ“ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Daily 8 AM โ€“ 11 PM).
  • โœ“ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
  • โœ“ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

The COL5A1 gene test is a definitive molecular diagnostic tool for Classical Ehlers-Danlos Syndrome (cEDS), utilizing Next-Generation Sequencing to detect pathogenic variants with unparalleled depth. This precise genetic examination aims to confirm the clinical diagnosis of Classical Ehlers-Danlos Syndrome, thereby enabling targeted management and health surveillance plans to be established.

Feature Our Test (Premium NGS) Closest Alternative (Single-Gene Sanger)
Methodology Next-Generation Sequencing (NGS) with full gene coverage & CNV analysis Sanger Sequencing of select exons
Diagnostic Sensitivity >99.9% for coding region variants ~90% (misses deep intronic & large del/dup)
Turnaround Time 3-4 Weeks 4-6 Weeks

Physician Insight & Safety Protocols

"This NGS-based test provides a molecular cornerstone for confirming Classical EDS, yet clinical correlation with skin fragility, joint hypermobility, and atrophic scarring remains paramount. I urge patients to view this not as an isolated data point, but as a catalyst for a comprehensive, multidisciplinary management plan coordinated with your specialist."

โ€” Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA Registration ID: 9294403)

Safety Advisory & Patient Guidance

Critical Clinical Considerations

Do not discontinue or adjust any prescribed medication, especially for cardiovascular or pain management, without explicit consultation with your attending physician. A negative genetic result does not exclude a clinical diagnosis of Ehlers-Danlos Syndrome; clinical correlation remains essential.

Exclusion Criteria for Home Collection

  • Severe Vasovagal Syncope: Patients with a documented history of severe fainting episodes during blood draws require a clinical site collection under medical supervision.
  • Active Chemotherapy: Individuals currently undergoing active chemotherapy must have sample collection arranged at their treating facility.
  • High-Dose Anticoagulation: Patients on high-dose anticoagulant therapy (INR > 3.5) require a clinical site draw post-physician clearance.
  • Emergency Red Flags: Seek immediate emergency care for sudden chest pain, acute vision changes, or severe unexplained bruising or bleeding, which may indicate vascular complications requiring urgent assessment.

Patient FAQ & Clinical Guidance

1. What exactly does the COL5A1 gene test diagnose?

This test identifies pathogenic DNA mutations in the COL5A1 gene to confirm a molecular diagnosis of Classical Ehlers-Danlos Syndrome (Type 1/2), guiding targeted management and surveillance strategies tailored to the patient's specific variant.

2. Is a session with a genetic counselor mandatory before this test?

A pre-test genetic counselling session is a mandatory prerequisite to draw a detailed three-generation family pedigree and ensure fully informed consent. This session ensures that patients understand the implications of all possible results, including incidental findings.

3. Can a dried blood spot on an FTA card be used for this NGS test?

Yes, a single drop of blood collected on a specialized FTA card is a validated, stable alternative to whole blood and extracted DNA. This method offers convenience for remote sample collection while maintaining high-quality nucleic acid preservation for downstream sequencing.

4. What is the recommended patient preparation before providing a blood sample?

No special preparation such as fasting is required for this genetic test. However, patients must complete a comprehensive clinical history form and participate in a mandatory genetic counselling session for familial pedigree charting prior to sample collection.

UAE Regulatory & Data Privacy Adherence

Regulatory Compliance Framework

  • Data Protection: All patient genomic data is processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring robust privacy safeguards and data subject rights.
  • Health Information Governance: Adherence to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields governs the secure handling, transmission, and storage of electronic health records and genetic data.
  • Clinical Safety & Consent: Patient safety protocols and informed consent procedures follow Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing that all clinical testing is conducted under the highest standards of medical accountability.
  • DHA Licensing: Laboratory operations are conducted under Dubai Health Authority Facility License Number 1143, ensuring compliance with all local healthcare regulations and quality benchmarks.

Clinical & Logistical Metadata

Test Name COL5A1 Gene Ehlers-Danlos Syndrome Type 1/2 Genetic Test
Price (AED) 2,800 AED
Turnaround Time 3 to 4 Weeks
Sample Type / Matrix Whole Blood (EDTA), Extracted DNA, or Dried Blood Spot on FTA Card
Methodology Used Next-Generation Sequencing (NGS) with full gene coverage & CNV analysis
ICD-10-CM Code Q79.6
LOINC Code 90207-0
DHA Facility License & Laboratory Address License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE

ุฏุนู… ุซู†ุงุฆูŠ ุงู„ู„ุบุฉ ู…ุชุงุญ

ุงู„ุชุญู‚ู‚ ู…ู† ุงู„ุชุบุทูŠุฉ ุงู„ุชุฃู…ูŠู†ูŠุฉ

Check Insurance Coverage Instantly

Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.

ุชูˆู‚ู ุนู† ุงู„ุชุฎู…ูŠู†. ุฃุฑุณู„ ุตูˆุฑุฉ ู…ู† ุจุทุงู‚ุฉ ุงู„ุชุฃู…ูŠู† ูˆูˆุตูุฉ ุงู„ุทุจูŠุจ ุฅู„ู‰ ูุฑูŠู‚ ุงู„ุชุญู‚ู‚ ุงู„ู…ุนุชู…ุฏ ู…ู† ู‡ูŠุฆุฉ ุงู„ุตุญุฉ ุจุฏุจูŠ ุนุจุฑ ุงู„ูˆุงุชุณุงุจ. ุงุญุตู„ ุนู„ู‰ ุชุญุฏูŠุซ ุงู„ุญุงู„ุฉ ููŠ ุฏู‚ุงุฆู‚.

โœ… DHA Certified โœ… ISO 15189 โœ… HIPAA Compliant

Available in Arabic, English, Hindi & Urdu

Preparation Required

["No special preparation such as fasting is required.", "Complete a comprehensive clinical history form.", "Participate in a mandatory genetic counselling session for familial pedigree charting."]

Medically Reviewed by Dr. Lina Osama Zaki Quteineh

All content reviewed by qualified professionals for accuracy.

๐Ÿ…

ISMS 27001:2022

๐Ÿ“‹

ISO Accredited

๐Ÿ”’

HIPAA

All reports reviewed by DHA-Certified physicians